Form 4: Higa Tomohiro reports sale transactions in TNYA

Q: What insider transaction did Tenaya Therapeutics (TNYA) report for Higa Tomohiro?

Tenaya reported that SVP, Finance Higa Tomohiro sold small amounts of common stock in three open-market transactions. These trades occurred on February 17, 2026 and were disclosed on a Form 4 insider transaction report.

Q: How many Tenaya Therapeutics (TNYA) shares did the SVP, Finance sell?

The SVP, Finance sold 611 , 836 , and 2,022 Tenaya Therapeutics common shares in three separate trades. Each transaction is reported individually, showing modest sale sizes rather than a single large disposition of stock.

Q: Why did Tenaya’s SVP, Finance sell TNYA shares according to the Form 4?

The filing explains that the shares were sold to cover tax withholding obligations triggered by vesting restricted stock units. Separate footnotes tie each sale to RSU awards granted in 2023 , 2024 , and 2025 , indicating a tax-related purpose.

Q: How many Tenaya Therapeutics (TNYA) shares does Higa Tomohiro still own?

After the reported transactions, he beneficially owns 119,752 Tenaya Therapeutics common shares directly. A footnote clarifies this figure includes 71,688 shares that will be issued when outstanding restricted stock units vest in the future.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Higa Tomohiro reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 3,469 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 122,610 shares.

Insider Trade Summary

Net Seller: 3,469 shares ($2,231)

Net Sell 3 txns

Insider Higa Tomohiro

Role SVP, Finance

Sold 3,469 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	611	$0.6434	$393.12
Sale	Common Stock	836	$0.6434	$537.88
Sale	Common Stock	2,022	$0.6431	$1K

Holdings After Transaction: Common Stock — 122,610 shares (Direct)

Footnotes (1)

Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Includes 78,314 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024. Includes 76,376 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025. Includes 71,688 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

02/17/2026 - 07:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Higa Tomohiro

(Last)

(First)

(Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Finance

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/17/2026		S⁽¹⁾		611	D	$0.6434⁽²⁾	122,610⁽³⁾	D
Common Stock	02/17/2026		S⁽⁴⁾		836	D	$0.6434⁽²⁾	121,774⁽⁵⁾	D
Common Stock	02/17/2026		S⁽⁶⁾		2,022	D	$0.6431⁽²⁾	119,752⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023.

2. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.6075 to $0.671. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. Includes 78,314 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

4. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 23, 2024.

5. Includes 76,376 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

6. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

7. Includes 71,688 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Tenaya Therapeutics (TNYA) report for Higa Tomohiro?

Tenaya reported that SVP, Finance Higa Tomohiro sold small amounts of common stock in three open-market transactions. These trades occurred on February 17, 2026 and were disclosed on a Form 4 insider transaction report.

How many Tenaya Therapeutics (TNYA) shares did the SVP, Finance sell?

The SVP, Finance sold 611, 836, and 2,022 Tenaya Therapeutics common shares in three separate trades. Each transaction is reported individually, showing modest sale sizes rather than a single large disposition of stock.

At what prices were the Tenaya Therapeutics (TNYA) shares sold?

The reported sales were executed at weighted average prices of about $0.6434 and $0.6431 per share. A footnote notes multiple trades within ranges from $0.6075 to $0.671, with full breakdowns available on request.

Why did Tenaya’s SVP, Finance sell TNYA shares according to the Form 4?

The filing explains that the shares were sold to cover tax withholding obligations triggered by vesting restricted stock units. Separate footnotes tie each sale to RSU awards granted in 2023, 2024, and 2025, indicating a tax-related purpose.

How many Tenaya Therapeutics (TNYA) shares does Higa Tomohiro still own?

After the reported transactions, he beneficially owns 119,752 Tenaya Therapeutics common shares directly. A footnote clarifies this figure includes 71,688 shares that will be issued when outstanding restricted stock units vest in the future.

Were derivative securities involved in this Tenaya Therapeutics (TNYA) Form 4 filing?

The Form 4 includes a section for derivative securities, but it shows no derivative transactions reported. The activity disclosed relates only to non-derivative common stock used to satisfy tax obligations from restricted stock unit vesting.